These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33761099)

  • 1. Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach.
    White S; Harris C; Allan M; Chieffe C; Eelen P; Röder C; Mouzawak C; Naylor ML
    Neurol Ther; 2021 Jun; 10(1):251-263. PubMed ID: 33761099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.
    Cordioli C; Callari G; Fantozzi R; Caruso F; Martucci G; Mascara S; Zipoli V
    Neurol Sci; 2021 Apr; 42(4):1515-1521. PubMed ID: 33439393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.
    Halper J; Centonze D; Newsome SD; Huang D; Robertson C; You X; Sabatella G; Evilevitch V; Leahy L
    Int J MS Care; 2016; 18(4):211-8. PubMed ID: 27551246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients - Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting - Results from the Non-Interventional Study PERFECT.
    Kukowski B; Rehberg-Weber K; Taipale K; Kowalik A; Oschmann P
    Patient Prefer Adherence; 2021; 15():1091-1100. PubMed ID: 34079229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
    Kolb-Mäurer A; Sunderkötter C; Kukowski B; Meuth SG;
    BMC Neurol; 2019 Jun; 19(1):130. PubMed ID: 31202258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.
    Hendin B; Huang D; Wray S; Naismith RT; Rosenblatt S; Zambrano J; Werneburg B
    Neurodegener Dis Manag; 2017 Feb; 7(1):39-47. PubMed ID: 28071330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers.
    Zhao Y; Chen K; Ramia N; Sahu S; Kumar A; Naylor ML; Zhu L; Naik H; Butts CL
    Ther Adv Neurol Disord; 2021; 14():1756286420975227. PubMed ID: 33628334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
    Hu X; Shang S; Nestorov I; Hasan J; Seddighzadeh A; Dawson K; Sperling B; Werneburg B
    Br J Clin Pharmacol; 2016 Aug; 82(2):380-8. PubMed ID: 27060836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
    Naismith RT; Hendin B; Wray S; Huang D; Gaudenzi F; Dong Q; Sperling B; Mann M; Werneburg B
    Mult Scler J Exp Transl Clin; 2019; 5(1):2055217318822148. PubMed ID: 30729026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
    Salvetti M; Wray S; Nelles G; Altincatal A; Kumar A; Koster T; Naylor ML;
    Mult Scler Relat Disord; 2022 Jan; 57():103350. PubMed ID: 35158459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
    Hendin BA
    Mult Scler Relat Disord; 2018 Nov; 26():33-36. PubMed ID: 30216756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
    Langeskov-Christensen M; Kjølhede T; Stenager E; Jensen HB; Dalgas U
    J Neurol Sci; 2016 Jun; 365():114-20. PubMed ID: 27206886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.
    Stewart TM; Tran ZV
    Int J MS Care; 2012; 14(1):46-53. PubMed ID: 24453732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.
    Newsome SD; Scott TF; Arnold DL; Nelles G; Hung S; Cui Y; Shang S; Naylor ML; Kremenchutzky M
    Ther Adv Neurol Disord; 2018; 11():1756286418791143. PubMed ID: 30181778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    Landi D; Albanese M; Buttari F; Monteleone F; Boffa L; Rossi S; Motta C; Puma E; Centonze D
    PLoS One; 2017; 12(7):e0165415. PubMed ID: 28686675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.